secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K/A
Filed at:   2026-07-15T21:09:08+00:00
Accession:  0001140361-26-028564
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics files Cullgen financials for merger; Cullgen FY2025 net loss $10.8M
--------------------------------------------------------------------------------

- Cullgen FY2025 net loss $10.8M, accumulated deficit $132.2M as of Dec 31, 2025.
- Cullgen revenue $15.4M from collaboration; R&D expense $19.3M, G&A $10.2M.
- Cullgen had $40.2M in cash and short-term investments; total assets $53.6M.
- Redeemable convertible preferred stock $173.5M; stockholders' deficit $127.4M.
- Merger closed May 4, 2026; this amendment provides required financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/0001140361-26-028564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/ef20077460_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer